Fertile sperm donor draws criticism from FDA, docs (Associated Press, 19 December 2011)

Novartis announces termination of Altitude study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment (Reuters, 20 December 2011)

21 Dec 2011

Novartis has announced that the ALTITUDE study with Rasilez®/Tekturna® (aliskiren) has been terminated following a recommendation of the independent Data Monitoring Committee (DMC) overseeing the trial.

Full article

Novartis announces termination of Altitude study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment (Reuters, 20 December 2011)

Share this story

Top stories

Most read